Seres Therapeutics, Inc. financial data

Symbol
MCRB on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 163% % 7.1%
Quick Ratio 37% %
Debt-to-equity 320% %
Return On Equity 15% % -75%
Return On Assets 3.6% %
Operating Margin -346791% % -654942%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9,046,519 shares -95%
Common Stock, Shares, Outstanding 8,764,664 shares -95%
Entity Public Float $87,098,863 USD -81%
Common Stock, Value, Issued $9,000 USD -95%
Weighted Average Number of Shares Outstanding, Basic 8,758,692 shares 15%
Weighted Average Number of Shares Outstanding, Diluted 8,771,519 shares 15%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $351,000 USD
Revenue from Contract with Customer, Excluding Assessed Tax $351,000 USD
Research and Development Expense $50,216,000 USD -6%
General and Administrative Expense $44,081,000 USD -8.7%
Operating Income (Loss) $103,430,000 USD 53%
Nonoperating Income (Expense) $108,824,000 USD
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $5,394,000 USD -91%
Earnings Per Share, Basic 0 USD/shares -58%
Earnings Per Share, Diluted 0 USD/shares -58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $47,638,000 USD -29%
Accounts Receivable, after Allowance for Credit Loss, Current $351,000 USD
Inventory, Net $52,997,000 USD 892%
Assets, Current $51,527,000 USD -29%
Property, Plant and Equipment, Net $8,578,000 USD -32%
Operating Lease, Right-of-Use Asset $74,669,000 USD -9.9%
Other Assets, Noncurrent $31,000 USD -93%
Assets $143,473,000 USD -20%
Accounts Payable, Current $1,677,000 USD -80%
Employee-related Liabilities, Current $4,444,000 USD -46%
Liabilities, Current $22,429,000 USD -65%
Operating Lease, Liability, Noncurrent $75,333,000 USD -12%
Other Liabilities, Noncurrent $2,014,000 USD 13%
Liabilities $99,776,000 USD -36%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD
Retained Earnings (Accumulated Deficit) $957,068,000 USD 0.56%
Stockholders' Equity Attributable to Parent $43,697,000 USD 83%
Liabilities and Equity $143,473,000 USD -20%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $26,910,000 USD
Net Cash Provided by (Used in) Financing Activities $1,180,000 USD -94%
Net Cash Provided by (Used in) Investing Activities $34,000,000 USD -54739%
Common Stock, Shares Authorized 360,000,000 shares 0%
Common Stock, Shares, Issued 8,764,664 shares -95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56,306,000 USD -27%
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $309,742,000 USD -0.98%
Deferred Tax Assets, Gross $330,857,000 USD -3.3%
Operating Lease, Liability $85,253,000 USD -8.9%
Payments to Acquire Property, Plant, and Equipment $34,000 USD -45%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $136,000 USD 62%
Lessee, Operating Lease, Liability, to be Paid $123,298,000 USD -14%
Property, Plant and Equipment, Gross $64,953,000 USD 0.33%
Operating Lease, Liability, Current $9,920,000 USD 19%
Lessee, Operating Lease, Liability, to be Paid, Year Two $20,582,000 USD 3%
Lessee, Operating Lease, Liability, to be Paid, Year One $19,983,000 USD 2.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $38,045,000 USD -22%
Lessee, Operating Lease, Liability, to be Paid, Year Three $20,863,000 USD 1.4%
Deferred Tax Assets, Operating Loss Carryforwards $156,157,000 USD 9.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $14,015,000 USD 3.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four $20,132,000 USD -3.5%
Operating Lease, Payments $17,561,000 USD -4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $4,264,000 USD -29%
Share-based Payment Arrangement, Expense $11,406,000 USD -49%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%